Industry update tracker: June 2026
A monthly index of company press releases and announcements shaping the real-world data (RWD), real-world evidence (RWE) and health technology assessment (HTA) landscape.
Atropos Health Expands Partnership with Databricks with the Launch of the Atropos Evidence Agent MCP on Databricks Marketplace
Atropos Health, the world's largest creator of RWE for clinical and medical decision-making, announced the launch of the Atropos Evidence Agent MCP on the Databricks Marketplace. The Databricks Marketplace is an open marketplace for data, analytics and AI, powered by OpenSharing. The Atropos Evidence Agent MCP joins a curated set of healthcare Model Context Protocol (MCP) servers on Databricks Marketplace — and is among a small group of proprietary offerings in the healthcare category. Together with its Databricks integration, the launch gives clinicians, researchers, and life sciences teams a streamlined path to generate real-world evidence on demand from inside the tools they already use.
Briya Opens Free Access to AIRE™, Bringing a Transparent AI-Powered Medical Research Platform to the Global Scientific Community
Briya announced no-cost access to AIRE™, its conversational scientific AI platform designed for clinical, epidemiological and RWE research. The launch opens advanced health research capabilities to a broader global scientific community through a transparent, browser-based SaaS environment built specifically for scientific inquiry. AIRE serves as the missing layer between fragmented healthcare data, generic AI models and trustworthy scientific evidence.
Century Health and Arizona Gastrointestinal Associates Partner to Accelerate Real-World Evidence in IBD and MASH
Century Health, a pioneer in applying AI to real-world clinical data to accelerate research, and Arizona Gastrointestinal Associates (AGA), an independent, physician-led gastroenterology network, today announced a partnership to transform real-world clinical data into research-grade datasets that support RWE generation and life sciences research for patients with inflammatory bowel disease (IBD) and metabolic dysfunction-associated steatohepatitis (MASH).
Enoda Launches Novel Platform to Deliver Real-World Mobility Data for Clinical Trials
Enoda, a new healthtech start-up, has announced the launch of a novel platform to deliver real-world mobility data to global pharmaceutical, medtech and clinical research partners. The data will enable them to gain unprecedented insight into how their therapies impact patient mobility in everyday life. Enoda’s novel platform, designed to meet the rigorous demands of modern clinical trials, is addressing this critical gap, empowering researchers and pharmaceutical companies with clinically meaningful, high-fidelity data to enhance patient insight and therapeutic development. Enoda recently spun-out of University College Dublin (UCD) and Newcastle University jointly with the support of NovaUCD and Newcastle Innovations and is an Enterprise Ireland High-Potential Start-Up (HPSU) company.
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
Genesis Research Group announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. Developed in-house by Genesis scientists and refined through two years of real-world application in client evidence work, EVID AI provides a structured environment for conducting evidence synthesis activities, from rapid evidence queries and targeted literature reviews to ongoing literature surveillance and end-to-end systematic reviews.
moveUP and Cascador Health Merge to Build a Data-Driven Digital Health Powerhouse
Cascador Health and moveUP have announced the completion of their merger, creating critical mass by combining two digital health specialists. The combined company already works with 8 of the top 10 global pharmaceutical companies, operates internationally, and supports more than 100,000 patients globally across its solutions. Customers include AstraZeneca, Sanofi, UCB and ArgenX. The joint company will go by the name of Cascador/moveUP and can rely on a multidisciplinary staff of 35 specialists based in Brussels and Ghent. Investors from both companies have invested €6 million in fresh capital alongside the merger – a signal of confidence in the strategy and recognition of the market position the companies have established in therapeutic areas such as epilepsy, orthopedics, respiratory immunology and rare diseases. The shared mission: to unlock the value of health data to help deliver the right treatment to the right patient at the right time.
Novellia Secures $18M Series A to Scale Patient-Powered Data Platform, Solving Pharma's $50B Problem
Novellia, the only RWD company built entirely on information patients choose to contribute to medical research, announced an $18 million Series A led by Spark Capital with participation from Khosla Ventures, Acrew Capital, Bling Capital, and TMV, bringing Novellia's total funding to $28 million. Building on this momentum, Novellia is also launching its patient-facing mobile app, an extension of its award-winning online platform that allows individuals to securely access their complete health history.
OneMedNet Surpasses 90 Million Patient Journeys and 270 Million Studies within its Network
OneMedNet Corporation, a leading provider of regulatory decision-grade, AI-Driven RWD, announced that its OneMedNet iRWD™ Network, has surpassed 90 million patient journeys and 270 million studies, with a healthcare partner network now exceeding 2300 sites. The milestone represents direct progress against the strategic priorities the Company laid out to shareholders at the close of 2025, when OneMedNet identified expansion of its data network as a core pillar of long-term value creation. The announcement reflects the team’s disciplined execution against that commitment – extending the breadth, depth, and connectivity of the network to meet accelerating demand for RWD and AI foundational models.
Samsung Partners With Alcedis to Advance Clinical Research Using Wearable-Based Endpoints
Samsung Electronics Co., Ltd. announced a partnership with Alcedis, a digital first clinical research organization (CRO) specializing in data-driven clinical trials, to translate biometrics collected by wearable devices into meaningful evidence for clinical trials in pharmaceutical and other research organizations, maximizing efficiency in terms of both cost and time.
Shionogi to Partner with ALS/MND Natural History Consortium to Collect Real-World Data in ALS, Reinforcing Investments in ALS Research
Shionogi & Co., Ltd. announced its continued partnership with the ALS/MND Natural History Consortium (Consortium) to collect real-world data in amyotrophic lateral sclerosis (ALS). The goal of this collaboration is to deepen scientific knowledge of ALS through access to real-world data, including data of approved therapies for ALS, such as RADICAVA ORS® (edaravone). By collaborating with the Consortium, Shionogi is contributing to a broader understanding of ALS as well as the therapeutic effects of currently approved treatments.
TriNetX LIVE™ Network Surpasses 300 Million Patients, Expanding Decision-Grade Evidence Across Global Healthcare
TriNetX, the world's leading federated health data network, today announced that its TriNetX LIVE™ network has surpassed 300 million patients, a single, federated source of EHR-native RWD spanning 240+ healthcare organizations and 13,000+ sites worldwide. The milestone expands the decision-grade evidence available to organizations working to improve patient care.
| Register for free today to become a member of The Evidence Base and receive the latest news straight to your inbox. |